Literature DB >> 2165110

Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia.

J D Meyers1, P Ljungman, L D Fisher.   

Abstract

Cytomegalovirus (CMV) viremia and excretion from the oropharynx and urine were examined for their utility in predicting the development of CMV disease, including pneumonia and gastrointestinal disease, among 617 marrow allograft recipients. CMV viremia had a 60% and excretion from oropharynx or urine or viremia a 44% positive predictive value for the development of CMV disease. Viremia or excretion preceded disease onset by a median of 15 days among those in whom excretion occurred first. In stepwise time-dependent proportional hazards regression analyses, CMV viremia and positive serology before transplant were predictive for both CMV pneumonia and gastrointestinal disease. Oropharyngeal excretion was independently predictive for gastrointestinal disease but not pneumonia. Urinary excretion was not independently predictive. Acute graft-versus-host disease was predictive for pneumonia but not gastrointestinal disease. Thus use of CMV excretion, particularly viremia, as a marker to determine the initiation of antiviral chemotherapy could be effective in preventing progression of infection to serious disease. However, with standard virologic techniques this strategy would not be effective in patients (32% in this study) without CMV excretion detected before the onset of pneumonia or gastrointestinal disease.

Entities:  

Mesh:

Year:  1990        PMID: 2165110     DOI: 10.1093/infdis/162.2.373

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Comparison of two commercial methods for measurement of cytomegalovirus load in blood samples after renal transplantation.

Authors:  C Y Tong; L E Cuevas; H Williams; A Bakran
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

Review 2.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients.

Authors:  R Delgado; C Lumbreras; C Alba; M A Pedraza; J R Otero; R Gómez; E Moreno; A R Noriega; C V Payá
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Risk factors for viral reactivation following bone marrow transplantation.

Authors:  D Pillay; A Webster; H G Prentice; P D Griffiths
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

5.  CD8 lymphocytosis in primary cytomegalovirus (CMV) infection of allograft recipients: expansion of an uncommon CD8+ CD57- subset and its progressive replacement by CD8+ CD57+ T cells.

Authors:  M Labalette; F Salez; F R Pruvot; C Noel; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

6.  Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection.

Authors:  Hideyuki Suzuki; Jun Kato; Motoaki Kuriyama; Sakiko Hiraoka; Kenji Kuwaki; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

7.  Cytomegalovirus Reactivation in Ulcerative Colitis Patients.

Authors:  Minh Nguyen; Kara Bradford; Xiaolan Zhang; David Q Shih
Journal:  Ulcers       Date:  2011-01-01

8.  Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

Authors:  R Mañez; S Kusne; M Green; K Abu-Elmagd; W Irish; J Reyes; H Furukawa; A Tzakis; J J Fung; S Todo
Journal:  Transplantation       Date:  1995-04-15       Impact factor: 4.939

9.  Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification.

Authors:  F S Nolte; R K Emmens; C Thurmond; P S Mitchell; C Pascuzzi; S M Devine; R Saral; J R Wingard
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 10.  Treatment of adenovirus infections in the immunocompromised host.

Authors:  P Ljungman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.